A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
NCT06611163
Recruiting
Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Medical Dermatology Specialists, Phoenix, Arizona +73 locations
Conditions: Moderate to Severe Genital Psoriasis
Register for Updates
Virtual A2 Study for At Risk Children
NCT06643598
Recruiting
The goal of this behavioral-interventional study is to learn if the Abecedarian Approach implemented virtually for children ages 0-5 with a history of Hypoxic Ischaemic Encephalopathy (HIE) and/or premature birth produces the same effects as when administered at in-person facilities.
Gender:
ALL
Ages:
5 years and below
Trial Updated:
07/22/2025
Locations: University of Wisconsin Madison, Madison, Wisconsin
Conditions: Hypoxic Ischaemic Encephalopathy (HIE), Premature Birth, Cerebral Palsy, Neurological Disorder
Register for Updates
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
NCT06655155
Recruiting
The main purpose of this study is to evaluate the effect and safety of efgartigimod PH20 SC compared to placebo in adults with systemic sclerosis. The study consists of a screening period, a treatment period of up to 48 weeks and a safety follow-up period. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod PH20 SC or placebo. The total study duration can be up to approximately 15 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona +18 locations
Conditions: Systemic Sclerosis (SSc)
Register for Updates
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549
Recruiting
The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/22/2025
Locations: Carey Chronis MD Pediatric, Infant and Adolescent Medicine, Ventura, California +36 locations
Conditions: Obesity, Overweight
Register for Updates
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
NCT06672939
Recruiting
The main purpose of this study, performed under Master Protocol J4M-MC-PWMP, is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
07/22/2025
Locations: Carey Chronis MD Pediatric, Infant and Adolescent Medicine, Ventura, California +39 locations
Conditions: Obesity, Overweight
Register for Updates
Using FAPI PET/MRI to Evaluate Prostate Cancer
NCT06675357
Recruiting
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer. Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Prostate Cancer Metastatic Disease, Prostate Cancers
Register for Updates
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
NCT06678659
Recruiting
This is a multi-center, open-label study to investigate the safety, tolerability, PK, PD, and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: City of Hope, Duarte, California +4 locations
Conditions: Unresectable, Locally Advanced, Metastatic Cancers, Relapsed/Refractory Lymphomas
Register for Updates
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
NCT06685718
Recruiting
This is an open-label, multicenter, Phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-60366, a highly potent, selective EGFR-mutation targeted Chimeric Degradation Activation Compound (CDAC). BG-60366 is designed to degrade mutant EGFR, which is a common cause for Non-Small Cell Lung Cancer (NSCLC). This study will evaluate how well BG-60366 works in participants with advanced or metastatic EGFR-mutant NS... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: University of Colorado, Denver, Colorado +42 locations
Conditions: Non-Small Cell Lung Cancer, Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), EGFR Activating Mutation, EGFR Mutation-Related Tumors
Register for Updates
A Study of LY4005130 in Healthy Participants
NCT06690996
Recruiting
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4005130 gets into the bloodstream and how long it takes the body to eliminate it. Part A for the single-ascending doses (SAD) of the study will last about 12 weeks with 9 visits. Part B for t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/22/2025
Locations: Fortrea Clinical Research Unit, Dallas, Texas
Conditions: Healthy
Register for Updates
How a Single Workout Affects Gut Bugs in Women With Different Fitness Levels and Body Types
NCT06691100
Recruiting
This study aims to elucidate the differences in the gut microbiome functional activity and metabolome in adult premenopausal women with distinctive fitness levels and BMIs (with obesity, w/o obesity). The specific aims are as follows: * Aim 1: To examine the effects of acute aerobic exercise at 60-70% heart rate reserve (HRRmax) for 30 minutes bout on changes in the abundance of SCFA-producing bacteria and their functional downstream metabolic activity. * Aim 2: To examine the effects of acute... Read More
Gender:
FEMALE
Ages:
Between 21 years and 40 years
Trial Updated:
07/22/2025
Locations: Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia
Conditions: Weight Management, Obesity, Exercise, Women, Gut Microbiome, Metabolome, Health, Gut Microbiota
Register for Updates
The RECAP2 Study: Midazolam and Psilocybin
NCT06692192
Recruiting
The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing. Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing. Participants will: * Receive one of four possible combinations of medications * Undergo an MRI * Complete question... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/22/2025
Locations: UW School of Medicine and Public Health, Madison, Wisconsin
Conditions: Psilocybin
Register for Updates
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
NCT06708897
Recruiting
This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and select low-grad lymphomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky +3 locations
Conditions: CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma)
Register for Updates